Kurser indlæses...

Prognose

Vi har ingen analytikerdata for denne virksomhed.

Diskussioner i communityet

Der er endnu ingen diskussion om dette aktiv.

Start diskussion

Nyheder Til nyhedsfeedet

AddLife reports stable Q1-2026 results and stock jumps sharply

AddLife recorded a 2% decline in net sales in the first quarter of 2026 due to currency effects and divestments, while organic growth adjusted was 3%. The EBITDA margin remained robust at 12.5% and profit before tax rose by 7%. Management emphasized a strategic focus on advanced products and acquisitions to boost margins. After the figures, the share price climbed 20.71% to 144.25, driven by positive investor reaction and an improved EPS outlook. » Mere på de.investing.com
AddLife misses revenue forecasts in first quarter

AddLife reported net sales of SEK 2.65 billion for the first quarter, below analysts’ expectation of SEK 2.74 billion; sales thus fell by 2%. Earnings per share were SEK 1.04, net profit SEK 128 million and EBITA SEK 332 million with an EBITA margin of 12.5%. Currency effects reduced revenue and EBITA by 4% each, organic growth was 3% and acquisition-driven growth 2%. During the quarter AddLife completed two acquisitions in the UK and Austria, but divestments and negative currency effects weighed on total sales. » Mere på de.investing.com
AddLife raises margins and reduces debt – shares jump 23%

AddLife reports a currency-adjusted revenue increase of 2% for Q4 2025 despite negative currency effects and a slightly improved EBITA margin of 12.4%. Operating cash-flow growth was strong (SEK 1,392 million), net debt fell by SEK 773 million and the net debt/EBITDA ratio is now 2.2. Two acquisitions (Pharmacold, Opitek) were completed at multiples below 7x EV/EBITDA; management is targeting roughly 15% earnings growth for 2026. » Mere på de.investing.com
AddLife records strong EBITDA growth in Q4 2025, shares climb over 23%

AddLife reported adjusted EBITDA growth of 5% for Q4 2025 and improved the full‑year EBITDA margin to 12.1% (from 10.5% in 2023). Despite negative currency effects that reduced revenue by 5% and EBITDA by 7%, operating cash flow in the quarter rose to SEK 900 million and annual cash flow reached SEK 1.4 billion. The share price jumped 23.22% to SEK 147.25; management plans multiple acquisitions in 2026 and targets 15% profit growth for 2026. Net debt stands at 2.2x EBITDA with a goal to remain below 3x. » Mere på de.investing.com
AddLife Registered B expects increase in revenue and profit in quarterly report

AddLife Registered B is expected to release its figures for the quarter ending June 30, 2025, on July 15, 2025. Analysts forecast a significant rise in earnings per share and a slight increase in revenue compared to the same quarter last year. Higher profits and revenues are also anticipated for the current fiscal year. » Mere på finanzen.net

Historisk udbytte Udbytte

Alle nøgletal for udbytte Alle nøgletal

I 2026 har AddLife B allerede udloddet 0,14 € i udbytte. Den seneste udlodning fandt sted i maj.

Virksomhedstal

I det seneste kvartal havde AddLife B en omsætning på 229,24 mio. € og et nettoresultat på 11,2 mio. €

(EUR)	september 2026	YoY
Omsætning	229,24 mio.	4,32 %
Bruttofortjeneste	88,11 mio.	7,26 %
Nettoresultat	11,2 mio.	52,86 %
EBITDA	34,49 mio.	4,73 %

Fundamentale data

Nøgletal	Værdi
Markedsværdi	1,93 mia. €
Antal aktier	117,29 mio.
Højeste/laveste i 52 uger	17,31 € - 11,98 €
Udbytteafkast	0,84 %
Udbytte TTM	0,14 €
Beta	1,57
P/E (PE Ratio)	34,62
PEG (PEG Ratio)	0,55
K/I (PB Ratio)	3,73
P/S (PS Ratio)	2,00

Virksomhedsprofil

AddLife AB (publ) leverer sammen med sine datterselskaber udstyr, medicinsk udstyr og reagenser primært til sundhedsvæsenet, forskning, universiteter og højskoler samt fødevare- og farmaceutisk industri. Virksomheden er organiseret i to segmenter, Labtech og Medtech. Labtech-segmentet tilbyder produkter, løsninger og services inden for diagnostik samt biomedicinsk forskning og laboratorieudstyr til hæmatologi, patologi, point-of-care-diagnostik, cellebiologi, genetik, mikrobiologi, virologi, molekylærbiologi, klinisk kemi, immunologi, forbrugsvarer og analyseinstrumenter. Segmentet tilbyder også support, vedligeholdelse, rådgivning og uddannelse. Medtech-segmentet leverer medicinske udstyrsprodukter til kirurgi, respiration, intensivbehandling, sårpleje, enteral ernæring, faldforebyggelse, velfærdsteknologi, øre-, næse- og halssegmentet samt badeværelsesrelaterede hjælpemidler og hjælpemidler til børn med handicap. Virksomheden er aktiv i Sverige, Finland, Danmark, Norge, Storbritannien, Irland, Tyskland, Italien, Østrig, Schweiz, resten af Europa og internationalt. AddLife AB (publ) blev grundlagt i 1906 og har hovedkontor i Stockholm, Sverige.